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successfully identifying 23 variants including the majority 
of the known causative ones. The application of the prior-
itization workflow to cancer datasets allowed to trim down 
the number of candidate for subsequent functional analyses, 
unveiling among these a high percentage of somatic vari-
ants. Prioritization criteria were implemented in both stan-
dalone (http://sourceforge.net/projects/mtoolbox/) and web 
version (https://mseqdr.org/mtoolbox.php) of MToolBox.
Introduction
The exponential growth of human mitochondrial DNA 
(mtDNA) sequences available in public databases (Bran-
don et al. 2005; van Oven and Kayser 2009; Rubino et al. 
2012) is probably the best current hallmark of the central 
role the mitochondrial genome plays in medicine, forensics 
and anthropology. In particular, clinicians have recently re-
discovered the ‘neglected genome’ (Pesole et al. 2012) as a 
pivotal determinant or modifier of an increasing number of 
pathologies, including Alzheimer (Adeghate et al. 2013), can-
cer (Verschoor et al. 2013), diabetes (Patti and Corvera 2010; 
Mercader et al. 2012; Adeghate et al. 2013), spinocerebellar 
ataxias (Mancini et al. 2013) and several types of sclerosis 
(Patti and Corvera 2010). Because the role of mtDNA vari-
ants in most of these phenotypes is still a matter of debate, 
it is fundamental that either novel or previously reported 
mtDNA variants of interest are highlighted and brought for-
ward to subsequent analyses, since functional studies aimed 
at ascertaining the potential pathogenicity often require cum-
bersome efforts. After sequencing and assembling an mtDNA 
genome, the first analytical step is usually the identification 
of positions differing from the chosen reference sequence. 
Next, with the aim of identifying variants of potential inter-
est for a disease or a particular phenotype, such positions 
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should be further filtered after determining the correct genetic 
background (haplogroup), so that fixed evolutionary allelic 
variants may be promptly recognized. Indeed, human mito-
chondrial phylogeny is described by haplogroup classification 
based on clusters of closely related evolutionary haplotypes, 
defined by the pattern of genetic markers occurring in the 
entire mtDNA and reflecting the migration of human popula-
tions over continents (Watson et al. 1997; Balter 2011).
Although clinicians are seldom familiar with the com-
plexity of haplogroups, evolutionary and adaptive aspects 
should not be ignored in clinical studies, whereby the 
genetic association between haplogroup-defining vari-
ants and clinical phenotypes has been traced (Ghelli et al. 
2009; Khan et al. 2013; Peng et al. 2013; Zhang et al. 2013). 
However, in the search for clinically relevant mtDNA vari-
ants, it is useful to rule out those evolutionary fixed, thus 
limiting variability analyses to few variants, annotated with 
estimation of conservation and prediction of pathogenicity, 
to obtain a shortlist of candidates that affect function of the 
gene/protein. Also, the heteroplasmic fraction of a sequence 
variant, whenever available, may not be neglected. Indeed, 
the advent of high-throughput sequencing technologies in 
mitochondrial genetics has revealed that a wide range of 
mtDNA variants at low heteroplasmy occurs also in healthy 
individuals (Payne et al. 2013; Diroma et al. 2014), and var-
ies among tissues (He et al. 2010).
Overall, there is an urgent need for a common workflow 
based on stringent criteria, to be implemented by research-
ers who face the challenge of in-depth analysis of mtDNA 
sequences, which would allow them to recognize the influ-
ence of few variants on the phenotype, thus facilitating the 
functional assay.
In this paper, we propose and validate a workflow for pri-
oritizing functionally important non-synonymous variants, 
starting from the variant annotation process already imple-
mented in MToolBox based on the use of the Macro Hap-
logroup Consensus Sequences (MHCS) (Calabrese et al. 
2014) and taking into account pathogenicity predictors. A 
nucleotide variability cutoff and a disease score threshold are 
established, to prioritize a pool of candidate variants affect-
ing function, which may then be further investigated. Disease 
scores and prioritization criteria are now implemented in both 
the standalone version (http://sourceforge.net/projects/mtool-
box/) as well as in the web version of MToolBox at MSeqDR 
portal (https://mseqdr.org/mtoolbox.php) (Falk et al. 2014).
Materials and methods
The MToolBox variant annotation process
MtDNA variants identified by the MToolBox pipeline 
(Calabrese et al. 2014) are thoroughly parsed through an 
annotation process which is mainly based on the compari-
son with both the two widely used rCRS and RSRS refer-
ence sequences and the recognition of alleles that are not 
shared with the sample-specific MHCS. MHCSs, integrated 
in the MToolBox package, were generated from 32 multi-
ple alignments of complete mitochondrial sequences from 
14,144 healthy individuals available in HmtDB (Novem-
ber 2013 update) belonging to the 32 chosen macro-hap-
logroups. Each macro-haplogroup-specific multi-alignment 
was then subjected to nucleotide composition analysis by 
applying the SiteVar algorithm (Pesole and Saccone 2001) 
to determine the allele occurring most frequently in each 
position thus generating the MHCSs.
The annotations provided by MToolBox for each variant 
include:
–– nucleotide site-specific variability estimated on the 
multi-alignment of the updated healthy genomes 
reported in HmtDB;
–– predictions of pathogenicity for non-synonymous vari-
ants by applying MutPred (Li et al. 2009), HumDiv- and 
HumVar-trained PolyPhen-2 models (Adzhubei et al. 
2013), SNPs&GO, PhD-SNP (Capriotti et al. 2013), 
and PANTHER algorithms (Thomas and Kejariwal 
2004). Each predictor assigns to each sequence variant 
a probability score of pathogenicity as well as a qualita-
tive prediction ‘disease’, ‘neutral’ or ‘unclassified’.
–– Mitomap (Lott et al. 2013) annotations referring to dis-
ease-associated mutations, occurring in coding and con-
trol regions and somatic mutations together with their 
state of homoplasmy/heteroplasmy;
–– links to OMIM (http://omim.org).
All these data are available in the ‘patho_table’, a tab 
delimited file provided by the MToolBox package, listing 
all possible 24,195 non-synonymous nucleotide substitu-
tions which may occur within the 13 human mitochondrial 
protein encoding genes, as previously reported (https://
sourceforge.net/projects/mtoolbox/; Pereira et al. 2011). 
Links to Mamit-tRNA (Pütz et al. 2007) web resources 
were added to provide the user with a general view of vari-
ants localization within the mitochondrial tRNA sequence 
structure.
Macro‑haplogroup consensus sequences (MHCS) 
phylogeny
The robustness of 32 MHCSs was tested by generating a 
phylogenetic tree including all MHCSs and two complete 
mitochondrial sequences, for each macro-haplogroup, 
derived from Phylotree (van Oven and Kayser 2009). Those 
sequences are also available in the Human mitochondrial 
Data Base (HmtDB—Rubino et al. 2012) which reports 
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all publicly available human mitochondrial genomes. 
Genomes associated to population studies are stored and 
analyzed as ‘healthy’; genomes from subjects affected by 
mitochondriopathies are reported in a separate category and 
annotated as ‘patient’. All data required to establish if an 
mtDNA genome sequence belongs to the ‘healthy’ category 
are obtained from the GenBank entry, papers and upon 
request to the authors. In addition, the multi-alignment and 
its manual editing allow to check the quality of sequences 
to detect any sequencing errors.
The MHCS phylogenetic tree was produced according 
to the Maximum Likelihood method, based on the Jukes–
Cantor substitution model (Jukes and Cantor 1969). The 
quality of the tree topology was assessed by bootstrap anal-
ysis of 500 replicates (Felsenstein 1985). Analyses were 
performed through the functions implemented in MEGA5 
software (Hall 2013).
Datasets
The prioritization workflow was validated on a dataset of 
125 mtDNA genomes belonging to individuals affected by 
Leber’s Hereditary Optic Neuropathy (LHON), sequenced 
by Sanger technology and stored in HmtDB (http://www.
hmtdb.uniba.it) (Rubino et al. 2012) (Supplementary 
Table 1—SampleData). This dataset was chosen to evaluate 
the performance of this workflow in identifying the known 
LHON-causative mutations since 42 % of these genomes 
was expected to harbor at least one of the primary muta-
tions included in the panel of the ‘Top 14 LHON’ annotated 
in Mitomap (Lott et al. 2013).
The efficiency of the workflow to prioritize and recog-
nize tumor-specific variants with a functional impact was 
also tested on mtDNA sequences obtained from 20 ovar-
ian cancer samples, collected within a concluded clini-
cal study, at S.Orsola-Malpighi Hospital, Bologna, Italy, 
during the period 2012–2013. Informed consent had been 
obtained in compliance with the Helsinki Declaration and 
the study had been approved by the local ethical commit-
tee. DNA was available also from the corresponding non-
tumor tissue of patients and was used in the context of this 
study to test the germline nature of identified variants. List 
of specimens and HmtDB identifiers, obtained after sub-
mission of sequences to the HmtDB, are reported in Sup-
plementary Table 2—SampleData. Sanger sequencing of 
the whole mtDNA was performed as previously described 
(Kurelac et al. 2013), to prevent nuclear mitochondrial 
sequence (NumtS) (Simone et al. 2011) co-amplification. 
The somatic (tumor-specific) nature of mitochondrial vari-
ants was ascertained by sequencing mtDNA from matched 
non-tumor tissue and validated on a second PCR product.
Finally, to test our workflow also on data generated from 
high-throughput technologies, Whole Exome Sequencing 
(WXS) BAM files (Binary Alignment/Map) from 90 
matched samples (primary solid tumor/peripheral blood) 
from Colorectal Adenocarcinoma (COAD) patients were 
downloaded from the online repository of the consortium 
dbGaP (https://cghub.ucsc.edu/). These data were gener-
ated from the Baylor College of Medicine (BMC) center of 
The Cancer Genome Atlas (TCGA, http://cancergenome.
nih.gov/) on Illumina platform and mapped on GRCh37-
lite reference (Genome Reference Consortium Human 
Build 37, accession = “GCA_000001405.1”). The samples 
featuring a mean read depth >10X across the mitochon-
drial genome after its extraction through MToolBox were 
brought forward in the analysis (Supplementary Table 3—
BloodSamples and TumorSamples sheets).
Denaturing high‑performance liquid chromatography 
(dHPLC) analysis on OC samples
For the variants found in Ovarian Cancer (OC) samples, 
PCR was performed using AmpliTaq Gold polymer-
ase (Applied Biosystems). For m.3380G>A in MT-ND1 
 fw-5′-ATACCCACACCCACCCAAGA-3′ and rv-5′-AGAT 
GTGGCGGGTTTTAGGG-3′ primers were used, for 
m.9837G>A in MT-CO3 fw-5′-TCAATCACCTGAGCT 
CACCA-3′ and rv-5′-ACCACATCTACAAAATGCCA 
GT-3′ primers were used, for m.14969T>A in MT-CYB 
fw-5′-AACTTCGGCTCACTCCTTGG-3′ and rv-5′-TCAC 
GGGAGGACATAGCCTA-3′ primers were used. The 
amplification product was analyzed by WAVE Nucleic 
Acid Fragment Analysis System (Transgenomic, Omaha, 
NE, USA). Data analysis was performed as previously 
described (Frueh and Noyer-Weidner 2003; Kurelac et al. 
2012).
Mitochondrial DNA extraction, variant detection 
and annotation
MToolBox pipeline (Calabrese et al. 2014), including sev-
eral steps as read mapping and NumtS filtering, post-map-
ping processing, genome assembly, haplogroup prediction 
and variant annotation, was used to extract the off-target 
mitochondrial genomes from the WXS COAD BAM files 
obtained from the TCGA repository, and then to annotate 
each variant allele. Fasta files from LHON and ovarian can-
cer samples were also used as input for MToolBox to anno-
tate mitochondrial variants and related features.
Disease Score definition for non‑synonymous variants
A training dataset of 53 mtDNA non-synonymous variants 
(Table 1; Supplementary Table 4), previously validated as 
affecting function, including 28 disease-associated mutations 
annotated in Mitomap as ‘confirmed’ to be pathogenic by 
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two or more independent laboratories (Lott et al. 2013), and 
25 clearly pathogenic cancer-associated mutations (Gasparre 
et al. 2007; Porcelli et al. 2010; Pereira et al. 2012), was used 
to define the ‘disease score’ (as described in the “Results” 
section ‘Disease Score definition’) of any non-synonymous 
mtDNA variants, by weighting the 6 above-listed pathogenic-
ity predictions (Thomas and Kejariwal 2004; Adzhubei et al. 
2013; Capriotti et al. 2013) available in the ‘patho_table’ 
implemented in MToolBox (https://sourceforge.net/projects/
mtoolbox/). These six methods were chosen among the most 
widely used pathogenicity predictors, available online for a 
fast evaluation of large-scale data from sequencing, although 
their often-contradictory predictions demand a way to weigh 
their reliability. More details regarding the features used by 
any method to predict the impact of amino acid allelic vari-
ants on protein structure/function are available in (Thomas and 
Kejariwal 2004; Adzhubei et al. 2013; Capriotti et al. 2013).
Disease Score threshold
To derive the Disease Score Threshold (DST) for assessing 
the potential functional impact of the non-synonymous vari-
ants, the mixture model of two normal distributions (McLa-
chlan and Peel 2000) was fitted to the disease scores related to 
1872 non-synonymous variants observed in 15,385 mtDNA 
genomes from healthy individuals, carefully selected as com-
plete sequences (http://webservice.cloud.ba.infn.it/hmtdb/
HmtDBHealthyGenomes_References.xlsx) and stored in 
HmtDB (May 2014, Rubino et al. 2012). It was not possible to 
define a DST from non-synonymous variants found in mtDNA 
genomes from patients, as stored in HmtDB. This dataset suf-
fered a sampling bias, in which certain pathologies (as LHON, 
Alzheimer’ disease, etc.) were over-represented, while others 
(as MELAS, etc.) were under-represented. The analysis was 
performed using the normalmixEM function from the mixtools 
package (Benaglia et al. 2009) implemented in R version 3.1.1.
Results
Macro‑haplogroup consensus sequences reliability
Based on the hypothesis that the mtDNA variants spread and 
fixed in one or more populations (e.g., haplogroup-defining 
variants) may be modifiers, but are less likely to be causa-
tive of a pathologic phenotype, the identification and prior-
itization of potentially pathogenic variants require retaining 
the rare ones, more prone to affect the gene/protein func-
tion (i.e., featuring high pathogenicity scores and occurring 
in highly conserved sites subjected to functional and selec-
tive constraints). In this perspective, comparing an mtDNA 
sequence to the related haplogroup-specific MHCS (Cala-
brese et al. 2014) may facilitate the process of prioritization 
by filtering out the fixed evolutionary variants and recogniz-
ing the rare ones. The consistency of MHCSs as consensus 
is supported by the clustering of such sequences with real 
Table 1  List of 53 non-synonymous variants composing the training dataset
The table lists non-synonymous variants and related locus previously validated as affecting the protein function and included in the training data-
set used to define the disease score
Non-synonymous variant Locus Non-synonymous variants Locus Non-synonymous variants Locus
T9185C MT-ATP6 T3931C MT-ND1 G10573A MT-ND4L
T9176C MT-ATP6 G3392A MT-ND1 G13042A MT-ND5
T9176G MT-ATP6 G3733A MT-ND1 T12706C MT-ND5
G8839A MT-ATP6 T3949C MT-ND1 T13540C MT-ND5
T8993C MT-ATP6 G3697A MT-ND1 G13513A MT-ND5
T8993G MT-ATP6 T3679C MT-ND1 A13514G MT-ND5
C6567T MT-CO1 G3922A MT-ND1 G13178A MT-ND5
T6210C MT-CO1 G4831A MT-ND2 T12797C MT-ND5
T15843C MT-CYB G4975A MT-ND2 T13847C MT-ND5
T15813G MT-CYB T10158C MT-ND3 T13271C MT-ND5
T15209C MT-CYB T10191C MT-ND3 C14568T MT-ND6
G3700A MT-ND1 G10197A MT-ND3 C14482A MT-ND6
C4171A MT-ND1 G12056A MT-ND4 C14482G MT-ND6
G3460A MT-ND1 T11613C MT-ND4 T14484C MT-ND6
T4222C MT-ND1 C11777A MT-ND4 A14495G MT-ND6
G3635A MT-ND1 G11778A MT-ND4 G14459A MT-ND6
G4148A MT-ND1 G11475A MT-ND4 T14487C MT-ND6
G3890A MT-ND1 T10663C MT-ND4L
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genomes belonging to the same haplogroup, as shown in the 
Supplementary Fig. 1. Hence, the simultaneous recognition 
of any variant with respect to rCRS (Andrews et al. 1999), 
RSRS (Behar et al. 2012) and MHCS was designed as the 
first step of the prioritization process to obtain a reliable pool 
of candidate variants, which may warrant further investiga-
tions. The 32 MHCSs will be updated according to the avail-
ability of new mtDNA sequences in the HmtDB database.
Disease Score definition
A high number of mtDNA variants annotated in the litera-
ture as ‘affecting function’ are non-synonymous mutations 
which involve the 13 protein-coding genes (Achilli et al. 
2012; Pereira et al. 2012), although high is also the number 
of mutations leading to functional damages in tRNA, rRNA 
and MT-DLOOP loci. The need to estimate the potential 
functional impact of any non-synonymous variant is hence 
a priority and yet the discrepancy of their pathogenicity pre-
dictions (Thomas and Kejariwal 2004; Adzhubei et al. 2013; 
Capriotti et al. 2013), when different algorithms are used, 
highlights the need for methods that may weigh the reliabil-
ity of predictors and yield a single pathogenicity score. A 
disease score was, therefore, defined based on the weighted 
mean of the probabilities that an amino acid substitution may 
affect gene/protein function, as provided by each pathogenic-
ity predictor. This score ranges between 0 and 1. The weight 
for each ith pathogenicity predictor was calculated as:
where hpi is the number of times the ith predictor out of six 
provides the highest probability for each training mutation 
(see “Materials and methods” section) to affect function, cpi 
is the number of times the ith algorithm performs a correct 
prediction confirming the functional impact of the previously 
validated mutations (Lott et al. 2013), and n is the number 
of mutations used for the training (Supplementary Table 4—
Training dataset). HumDiv- and HumVar-trained PolyPhen-2 
models (Adzhubei et al. 2013) were the most effective predic-
tors for the training non-synonymous mutations based on the 
established weights. The Disease Score (DS) of a non-synon-
ymous variant was then calculated as reported in “Box 1”.
Wi = (hpi + cpi)/2n
Prioritization criteria of mtDNA non‑synonymous 
variants
A Disease Score Threshold (DST) and a nucleotide vari-
ability cutoff (NVC) were then established to discriminate 
non-synonymous mtDNA variants contributing to a poten-
tial defective phenotype among the candidate rare ones. 
The distribution of DSs (as described in “Box 1”) for the 
non-synonymous variants observed in the mtDNA genomes 
from healthy individuals (see “Materials and methods” 
section), highlighted a mixture of two normal compo-
nents (McLachlan and Peel 2000) shown in the histogram 
(Fig. 1a). It was assumed that the second component of 
the mixture model with the highest disease score values 
potentially included the most damaging variants, since the 
DS of variants predicted by all pathogenicity predictors as 
‘neutral’ or ‘disease’ did not overlap (Fig. 1b). The DST 
was chosen as the lowest DS value by which the prob-
ability to belong to the second mixture model component 
is ten times greater than the probability to belong to the 
first one (0.4311—Fig. 1a). Variants showing a DS above 
0.4311 may, therefore, be considered potentially functional. 
Moreover, an additional DST was also calculated on dis-
ease scores distribution of ‘all possible non-synonymous 
variants’, as reported in the patho-table provided with 
MToolBox (Calabrese et al. 2014). A bimodal distribution 
of the DSs, similarly to that for non-synonymous variants 
observed in healthy individuals, was obtained (Supplemen-
tary Fig. 2). In this case, however, the second component of 
the mixture model underlined a higher number of variants, 
never occurred in any mtDNA sequence, with DSs higher 
than those from healthy genomes. This very high DST may 
underestimate the potential functional impact of a vari-
ant, since the majority of variants showing a very high DS 
have never been observed in mtDNA genomes from both 
healthy and diseased individuals. Furthermore, by taking 
into account the nucleotide variability values associated to 
the 816 observed non-synonymous variants featuring dis-
ease score above the established DST (Fig. 1c), we chose 
the third quartile of this distribution as nucleotide vari-
ability cutoff (NVC) for variants with a possible functional 
impact. The resulting NVC was 0.0026. The established 
Box 1: Disease score (DS)
 
where MPp = MutPred probability, PPDp = Polyphen-2 HumDiv probability, PPVp = Polyphen-2 HumVar probability, 
PTp = PANTHER probability, PSp = PhD-SNP probability, SGp = SNPs&GO probability, MPw = MutPred weight, 
PPDw = Polyphen-2 HumDiv weight, PPVw = Polyphen-2 HumVar weight, PTw = PANTHER weight, PSw = PhD-
SNP weight, SGw = SNPs&GO weight.
DS =
(MPp×MPw)+ (PPDp× PPDw)+ (PPVp× PPVw)+ (PTp× PTw)+ (PSp× PSw)+ (SGp× SGw)
MPw+ PPDw+ PPVw+ PTw+ PSw+ SGw
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cutoffs were applied to the dataset of all possible non-syn-
onymous mitochondrial variants (reported in ‘patho_table’ 
implemented in Calabrese et al. 2014; https://sourceforge.
net/projects/mtoolbox/), selecting the 70.8 % of variants 
as potentially functional on the strength of both nucleotide 
variability lower than 0.0026 and disease score higher than 
0.4311.
In summary, by taking into account the functional anno-
tation already implemented in MToolBox (Calabrese et al. 
2014), the in silico prioritization criteria here proposed 
are intended to easily target the mtDNA variants that most 
likely affect the gene/protein function, by prioritizing those 
non-synonymous variants (1) simultaneously identified 
by rCRS, RSRS and MHCS, (2) non-haplogroup defin-
ing, (3) featuring nucleotide variability lower than NVC 
and (4) having a disease score above the DST. In addition, 
variants showing heteroplasmy levels greater than or equal 
to a user-established value were included among the vari-
ants potentially impacting on phenotype. The prioritiza-
tion process was tested on samples from the three different 
datasets: a series of LHON mtDNA sequences was used in 
representation of one of the most widely studied canoni-
cal mitochondrial diseases; an ovarian cancer and a COAD 
dataset were used with the aim to test the workflow for its 
ability to recognize potentially functional tumor-specific 
variants starting from both Sanger sequencing and Whole 
Exome (WXS), respectively.
LHON‑derived samples variant prioritization analysis
LHON is a paradigmatic mitochondrial disorder usually 
caused by mtDNA point mutations leading to amino acid 
Fig. 1  a The histogram graphs the bimodal distribution of dis-
ease scores associated to 1872 non-synonymous variants (HmtDB, 
May 2014) observed in mtDNA sequences from healthy individu-
als and stored in HmtDB. The solid lines indicate the two gaussian 
components of the mixture model (McLachlan and Peel 2000) (46 
and 54 %, respectively). The first component of the mixture model 
with the lowest disease score values included the most benign non-
synonymous variants. The vertical dashed line is drawn at the 
selected Disease Score Threshold, DST, defined as 0.4311; non-
synonymous variants featuring a DS above 0.4311 may, therefore, 
be considered potentially affecting function. b Box-plot diagram 
shows the disease scores of non-synonymous variants by class of 
‘Neutral’ or ‘Disease’ prediction (disease scores ranging from 0.05 
to 0.4311 and from 0.6565 to 0.9162, respectively, for each class) as 
returned by all six pathogenicity predictors implemented in MTool-
Box. Circles represent the outliers. c Empirical cumulative distribu-
tion function of nucleotide variability associated with the 816 non-
synonymous variants, featuring a disease score above the established 
DST. Dashes vertical line indicates the nucleotide variability cutoff, 
NVC = 0.0026, defined as the third quartile of such distribution. 
Non-synonymous variants showing variability values below the NVC 
are filtered by the variant prioritization workflow
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changes in genes encoding the subunits of complex I of the 
mitochondrial respiratory chain (Abu-Amero and Bosley 
2006). Genes MT-ND1 and MT-ND6 are reported as hot-
spots for LHON-causative mutations (Reynier et al. 1999; 
Valentino et al. 2004; Fraser et al. 2010), which harbor ‘14 
Top primary mutations’ (Wallace et al. 1988; Howell et al. 
1991; Johns et al. 1992; Brown et al. 1995; Chinnery et al. 
2001; Kim et al. 2002; Gropman et al. 2004; Achilli et al. 
2012) annotated in Mitomap (Lott et al. 2013).
To evaluate the performance of the prioritization criteria 
in identifying the known causative LHON mutations and/
or suggesting novel variant candidates for further analy-
ses, the prioritization process was applied to 125 LHON-
derived mtDNAs. The workflow is shown in Fig. 2a. We 
identified 926 variants with an average of 72 variants per 
genome (Supplementary Table 1). We first focused on the 
subset of variants recognized by rCRS, RSRS and MCHS 
and occurring in non-haplogroup-defining sites. Among 
these, only 142 variants were brought forward in the analy-
sis since they occurred in positions subjected to functional 
constraint and then featuring variability values lower than 
or equal to the NVC value. Next, we filtered the variants 
mapping on the protein-coding regions and leading to an 
amino acid change, and evaluated them on the strength of 
their DS. 23/51 non-synonymous variants (2.5 % of total 
variants) identified in 66.4 % of 125 analyzed LHON-
derived genomes and featuring a disease score above the 
chosen DST were prioritized as probably affecting func-
tion (Fig. 2a). The genomes analyzed harbored 11 out of 
14 Top primary LHON mutations; the prioritization process 
selected 8 out of 11 leaving out m.3700G>A, m.14502T>C 
and m.14484T>C (Table 2). Specifically, the rare mutation 
m.3700G>A (MT-ND1) was not included, as it featured 
a disease score (DS = 0.35) lower than the chosen DST, 
suggestive of a benign behavior of the resulting amino 
acid change on protein function, even though absent in 
the healthy population (nucleotide variability = 0.00). 
The mutation m.14502T>C (MT-ND6) was found in two 
genomes (PA_EU_DE_0006; PA_AS_CN_0071, the lat-
ter showing also the mutation m.14484T>C) and discarded 
because both DS and NV were outside of the fixed thresh-
olds. Finally, the mutation m.14484T>C (MT-ND6) found 
in 95 % of LHON cases was not prioritized due to its NVC 
higher than the threshold (NV = 0.0046). The list of prior-
itized variants included also those ones showing the same 
pathogenicity features of the ‘Top 14 LHON-causative 
mutations’ (Table 2). Interestingly, they were not previously 
associated with LHON and, therefore, may warrant further 
investigation. Furthermore, the multi-parametric workflow 
was again applied to LHON dataset by removing the filter-
ing step ruling out the haplogroup-defining variants. In that 
case, the list of prioritized variants counted only two addi-
tional variants: m.14337C>T and m.15038A>G, respec-
tively, defining the sample-specific M10a1a1 and B4d1 
haplogroups, simultaneously recognized by the three refer-
ences and featuring variability values lower than NVC and 
disease scores above the established DST, but not annotated 
in Mitomap.
Identification of somatic variants in ovarian cancer
Mitochondrial variants have been frequently detected in 
cancer (Brandon et al. 2006; Jandova et al. 2012), likely as 
secondary modifier mutations, or as indirect consequences 
of driver mutations in nuclear genes (Schon et al. 2012). 
We next sought to determine whether our workflow allows 
recognizing variants in cancer samples. We started from the 
assumption that cancer cells are prone to acquire mtDNA 
Fig. 2  The stepwise prioritiza-
tion workflow and the related 
number of mitochondrial 
variants filtered in any step per-
formed on the full lists of any 
detected variants annotated in A 
LHON and B ovarian datasets 
from Sanger sequencing
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variants due to their continuous replication (Coller et al. 
2001). Moreover, most often only cancer cells are able to 
cope with highly pathogenic mtDNA mutations, since they 
have a deranged energy metabolism (Brandon et al. 2006; 
Iommarini et al. 2014). One of the problems encountered in 
assessing mtDNA mutations in cancer is the need to define 
whether such variants are truly somatic, in which case they 
may be inferred to be modifiers of tumor progression. We 
hence attempted to test whether our workflow was able to 
highlight candidate variants for being somatic, that only 
transformed cells may withstand in the context of a deregu-
lated cell metabolism. This would avoid sequencing of the 
whole mtDNA of the non-cancer tissue, which is seldom 
available particularly for cancers whose nature does not 
allow resection of surrounding normal tissue (e.g., glioblas-
toma). To this aim, we exploited 20 mtDNA sequences we 
had obtained in the context of a clinical study on ovarian 
cancer, derived from 20 different ovarian carcinomas. For 
each of these samples, dissected tumor and normal peritu-
moral tissue were available. Implementation of the work-
flow on the 20 cancer mtDNAs revealed 268 variants (Sup-
plementary Table 2), with an average of 65.2 variants per 
sample. 212/268 variants were flagged by all three refer-
ence sequences, namely rCRS, RSRS and MCHS, and were 
brought forward in the analysis. Of these, 110 mapped in 
non-haplogroup-defining sites, and were further brought 
forward. 39/110 variants featured a variability value below 
the NVC. We focused on variants in protein-coding regions 
since predictions of pathogenicity were available exclu-
sively for non-synonymous variants. 28 of the 39 variants 
mapped in protein-coding regions. Of the latter, 14 were 
silent and 13 were non-synonymous. The steps of the pri-
oritization workflow are shown in Fig. 2b. Since we could 
not rule out a partial contamination by non-tumor stromal 
cells, which may lead to underestimation of the hetero-
plasmy fraction, we decided to apply a 0.50 cutoff criterion, 
Table 2  List of prioritized non-synonymous variants in LHON samples
Non-synonymous variant recognized on LHON-derived mtDNAs and prioritized according to the established criteria. Number of samples har-
boring the variant allele (No. samples), mtDNA locus (locus), site-specific nucleotide variability value (Nt Var), amino acid change and vari-
ability (AA change and AA Var, respectively), Disease Score, annotations from Mitomap (Lott et al. 2013) and frequencies in 1000 genomes 
[as implemented in (Calabrese et al. 2014)] are associated with each variant allele. Frameshifts and Premature stop codons are also reported in 
‘AA change’ field. None of the LHON variants are involved in haplogroup assignment. For full variants in LHON samples, see Supplementary 
Table 1
LDYT Leber’s hereditary optic neuropathy and Dystonia, LS Leigh syndrome, OA optic atrophy, PE progressive encephalomyopathy, PDY pro-
gressive dystonia
No. samples Variant allele Locus Nt Var AA change AA Var Disease score Mitomap 1000 genomes
1 10747A MT-ND4L 0.0000 L93Q 0 0.8781
1 6448A MT-CO1 0.0000 P182H 0.0026 0.8325
1 7042C MT-CO1 0.0000 V380A 0.0047 0.8044
1 15156G MT-CYB 0.0003 Q137R 0.0005 0.9044
1 7632C MT-CO2 0.0003 I16T 0.0018 0.4579
1 9104C MT-ATP6 0.0007 F193S 0.0075 0.5168
1 14249A MT-ND6 0.0016 A142 V 0.0121 0.4498
1 8551C MT-ATP6 0.0018 F9L 0.0042 0.7620 0.0008
1 3890A MT-ND1 0.0000 R195Q 0 0.8184 PE/LS/OA
2 3733A MT-ND1 0.0000 E143 K 0 0.8360 LHON Top 14
9 3635A MT-ND1 0.0000 S110 N 0 0.7977 LHON Top 14
1 3733C MT-ND1 0.0000 E143Q 0 0.8677 LHON
1 3922A MT-ND1 0.0000 E206 K 0 0.8939 Head/neck tumor
1 14495G MT-ND6 0.0000 L60S 0 0.8616 LHON Top 14
1 10663C MT-ND4L 0.0000 V65A 0 0.5776 LHON Top 14
1 14841G MT-CYB 0.0000 N32S 0 0.8360 LHON helper mut. 0.0012
1 9655A MT-CO3 0.0005 S150 N 0.0029 0.7259 Thyroid tumor 0.0008
1 14459A MT-ND6 0.0006 A72 V 0.0183 0.8655 LDYT/LS/LHON Top 14 0.0008
4 14568T MT-ND6 0.0009 G36S 0.0079 0.7311 LHON Top 14
15 3460A MT-ND1 0.0014 A52T 0.0015 0.7629 LHON Top 14 (95 %)
2 4171A MT-ND1 0.0016 L289 M 0.0107 0.6809 LHON Top 14
2 14482A MT-ND6 0.0024 M64I 0.0333 0.7923 LHON Top 14
41 11778A MT-ND4 0.0025 R340H 0.0516 0.8534 LHON Top 14 (95 %)/PDY 0.0004
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upon estimation of heteroplasmy based on the ratio of peaks 
height on the electropherograms. Overall, 8/13 non-synony-
mous variants featuring a disease score above the DST, and 
the frameshift event m.6691insA were finally included in 
the list of candidate variants for being somatic (Table 3). We 
next verified whether the prioritized variants were indeed 
somatic (cancer-specific). Sequencing of the specific ampli-
con including each of the 9 prioritized variants starting from 
non-tumor tissues of the corresponding samples revealed 
that 7/9 variants (78 %) were absent in the non-tumor tissue 
and, therefore, cancer-associated, whereas 2/9 non-synony-
mous variants were also detected in non-tumor specimens 
(22 %) (Table 3). A further DHPLC analysis for the detec-
tion of low heteroplasmy (down to 2 %—Kurelac et al. 
2012) randomly performed on three cancer-associated vari-
ants, revealed that all three were indeed absent from the nor-
mal tissue, confirming with a much more sensitive method 
than Sanger sequencing their true somatic nature (Supple-
mentary Fig. 3). Interestingly, the two non-somatic variants 
among the prioritized ones were those featuring the lowest 
DS and the highest NV, suggesting our criteria for inclusion 
could be made even more stringent. As a final check, we 
also specifically sequenced the 14 silent variants in the non-
tumor specimens from corresponding cancer samples and 
they all resulted germline, indicating that the NV param-
eter is necessary but not sufficient to infer somaticity. The 
list of prioritized variants obtained performing the whole 
multi-step workflow on this dataset did not differ from that 
obtained by removing the haplogroup-filtering step.
Mitochondrial DNA sequences extraction from COAD 
samples
Numerous studies report somatic mutations in mtDNAs 
from colorectal cancer patients (Alonso et al. 1997; Polyak 
et al. 1998; Lièvre et al. 2005; He et al. 2010; Wang et al. 
2011) but the correct pattern of COAD-associated mutations 
has not been yet reconstructed (Skonieczna et al. 2012).
The availability of WXS data obtained by The Cancer 
Genome Atlas (TCGA) repository provided an extensive 
characterization of the occurrence of mtDNA variants, also 
at low heteroplasmy levels, in COAD. Accordingly, we 
tested the efficiency of our workflow to prioritize a small 
pool of functionally important variants from the huge 
amount of data from high-throughput sequencing in this 
dataset. Pairwise comparison of blood and tumor mtDNA 
variants was performed to identify germline and tumor-spe-
cific mitochondrial variants.
The assembly of mitochondrial WXS reads derived from 
COAD matched tumor and blood samples showed a mean 
read depth of 304.86X (median = 258.31X) and 155.88X 
(median = 127.94X), respectively. The values of mean 
read depth ranged between 14.90X and 525X in blood and 
between 13.48X and 1274X in tumor samples. Specifically, 
the tumor dataset showed a significantly higher read depth 
(Wilcoxon test, p value = 3.194e−06) (Supplementary 
Table 3—BloodSamples, TumorSamples).
Tumor‑specific variants in COAD samples
We applied the prioritization process on the full list of 
tumor-specific variants identified in 86/90 tumor samples 
(Supplementary Table 2—TumorSpecific). 1130 variants 
were identified against rCRS, RSRS and MCHS, all map-
ping on non-haplogroup-defining sites (Fig. 3a). The lack 
of somatic variants in 4 tumor samples could likely be 
ascribed to a low mean depth coverage. An average of 14.5 
variants per sample was identified. The 82 % of total vari-
ants was filtered as featuring a variability value below the 
chosen NVC. We next focused on the 574 variants mapping 
Table 3  List of prioritized mtDNA non-synonymous variants in ovarian cancer samples
Tumor-specific and germline variants recognized on ovarian cancer-derived mtDNAs and prioritized according to the established criteria. Sam-
ple identifier (sample), heteroplasmic fraction (HF), mtDNA locus (locus), site-specific nucleotide variability (Nt Var), Amino acid change and 
variability (AA change and AA Var, respectively), Disease Score, somatic (+) or germline (−) nature (‘tumor-specific/germline’) of variants and 
frequencies in 1000 genomes [as implemented in (Calabrese et al. 2014)] are associated with each variant allele. For full variants in ovarian can-
cer samples, see Supplementary Table 2—AllVariants
Sample Variant allele HF Locus Nt Var AA change Tumor-specific AA Var Disease score 1000 genomes
EOC5 3380A 0.8 MT-ND1 0.0003 R25Q + 0.00 0.8764 0.0004
EOC40 14969C 0.5 MT-CYB 0.0003 Y75H + 0.00 0.8526 0.0004
EOC16 9837A 0.5 MT-CO3 0.0000 G211S + 0.00 0.8379 0.0004
EOC20 15255C 0.8 MT-CYB 0.0000 V170A + 0.00 0.8195 0.0004
EOC20 10696T 0.8 MT-ND4L 0.0000 A76 V + 0.01 0.7810
EOC14 6121C 0.5 MT-CO1 0.0007 I73T + 0.00 0.7054 0.0004
EOC5 8412C 1.0 MT-ATP8 0.0023 M16T − 0.03 0.6587 0.0008
EOC32 14249A 1.0 MT-ND6 0.0020 A142 V − 0.02 0.4498
EOC37 6691.A 0.5 MT-CO1 0 Frameshift + 0
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in the protein-coding regions. Among these, we identified 
a subset of 350 non-synonymous variants featuring a dis-
ease score above the DST and corresponding to 31 % of all 
annotated variants. We reasoned that 0.8 would be a reason-
able heteroplasmic fraction (HF) cutoff to include poten-
tially affecting function variants with a clear impact on the 
phenotype, a threshold that is often used as mtDNA vari-
ants impact on bioenergetics when 4/5 mtDNA copies are 
mutated (Chinnery et al. 1997; White et al. 1999; Gasparre 
et al. 2011; Chinnery and Hudson 2013; Keogh and Chin-
nery 2013); this additional filtering step drastically reduced 
the number of candidate non-synonymous variants to 21 
(Fig. 3a) and the number of variants leading to premature 
stop codons to 2. The prioritization criteria were able to pri-
oritize only the 2 % of tumor-specific variants on the 25 % 
of COAD samples (Table 4). This list included 19 variants 
not annotated in Mitomap, while the mutations m.3946G>A 
and m.3380G>A were found associated to Mitochondrial 
Encephalomyopathy, Lactic Acidosis, and Stroke-like epi-
sodes (MELAS), m.15243G>A and m.7623C>T to Hyper-
trophic Cardiomyopathy (HCM) and LHON, respectively. 
Finally, the mutation m.14918G>A, found in two samples, 
was the only one previously associated to colorectal cancer. 
Germline variants in COAD samples
The process of prioritization was then applied on the data-
set of variants shared between matched blood-tumor pairs 
to identify potentially pathogenic germline candidates 
that may represent predisposing variants. The filtering 
steps applied on the 716 germline variants, with an aver-
age of 64 variants per sample, identified in all COAD indi-
viduals (Supplementary Table 3—Germline), are shown 
in Fig. 3b. 76 % of total variants was recognized against 
rCRS, RSRS and MCHS while 27 % occurred in non-
haplogroup-defining sites. 8 % of fully annotated variants 
was then filtered as featuring variability value below the 
established NVC, 9 non-synonymous variants remained. 
Among these, 7 showed a disease score above the DST. 
To further trim down the number of the suitable germline 
candidates for subsequent functional analyses, these were 
filtered for HF levels above 0.8, leading to prioritization 
of 4 variants (with confidence interval (CI) overlapping in 
both tumor and blood samples), corresponding to 0.56 % 
of total (Table 5). None of the prioritized germline vari-
ants had been previously annotated in Mitomap and may, 
therefore, deserve further investigation. The total number 
of prioritized variants on the strength of the criteria here 
proposed in the 90 COAD samples included 25 variants. 
Among these, 84 % of variants resulted to be tumor spe-
cific. It is worth noting that 266 variants were exclusively 
identified in 53/90 blood samples (Fig. 3; Supplementary 
Table 3—BloodSpecific), with an average of 3 variants per 
sample. Two hundred and sixty-one out of 266 variants 
were recognized against rCRS, RSRS and MCHS, all map-
ping on non-haplogroup-defining sites. Among these, 206 
Fig. 3  The stepwise prioritiza-
tion workflow and the related 
number of mitochondrial 
variants filtered in any step per-
formed on the full lists of any 
detected A tumor-specific and B 
germline variants annotated in 
the COAD dataset from Whole 
Exome Sequencing (WXS). The 
number of blood-specific vari-
ants is also shown
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Table 4  List of tumor-specific non-synonymous variants prioritized in COAD samples
Tumor-specific variants recognized on COAD-derived mtDNAs and prioritized according to the established criteria. Sample identifier (sample), 
heteroplasmic fraction (HF), mtDNA locus (locus), site-specific nucleotide variability (Nt Var), amino acid change and variability (AA change 
and AA Var, respectively), Disease Score, annotations from Mitomap (Lott et al. 2013) and frequencies in 1000 genomes [as implemented in 
(Calabrese et al. 2014)] are associated with each variant allele. For full tumor-specific variants in COAD samples, see Supplementary Table 3—
TumorSpecific
HCM hypertrophic cardiomyopathy, MELAS mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
Sample Variant 
allele
HF Locus Nt Var AA change AA Var Disease 
score
Mitomap 1000 genomes
A6665101A21D183510 11390A 0.861 MT-ND4 0.0002 Premature Stop 
Codon
0.01
A6665201A11D177110 3380A 0.967 MT-ND1 0.0003 R25Q 0.00 0.8800 MELAS 0.0004
AU377901A01D171910 10863A 0.909 MT-ND4 0.0003 S35N 0.00 0.7600
CM474301A01D171910 14918A 0.814 MT-CYB 0.0003 D58N 0.00 0.7100 0.0004
14985A 0.881 MT-CYB 0.0000 R80H 0.00 0.9000 Colorectal tumor 0.0017
CM534401A21D171910 11552C 0.819 MT-ND4 0.0000 S265P 0.00 0.8900
CM586101A01D165010 12814A 0.979 MT-ND5 0.0011 A160T 0.00 0.6900 0.0004
CM586401A01D165010 10854C 0.971 MT-ND4 0.0000 L32P 0.00 0.8500 0.0008
CM616401A11D165010 15243A 0.874 MT-CYB 0.0000 G166E 0.00 0.9000 HCM 0.0004
CM616501A11D165010 3946A 0.935 MT-ND1 0.0001 E214K 0.00 0.9100 MELAS 0.0012
D5653501A11D171910 9645A 0.861 MT-CO3 0.0000 A147T 0.00 0.8100 0.0004
D5654101A11D171910 4810A 0.9 MT-ND2 0.0000 Premature Stop 
Codon
0.00
D5693001A11D192410 6798A 0.866 MT-CO1 0.0000 V299M 0.00 0.7700
DMA0X901A11DA1521 3380A 0.799 MT-ND1 0.0003 R25Q 0.00 0.8800 MELAS 0.0004
9790T 0.949 MT-CO3 0.0000 S195L 0.00 0.8300
DMA1D001A11DA15210 4537A 0.925 MT-ND2 0.0000 S23N 0.00 0.8200
DMA1DA01A11DA15210 8243A 0.954 MT-CO2 0.0000 E220K 0.00 0.7300 0.0008
DMA28501A11DA16V10 10233A 0.935 MT-ND3 0.0000 A59T 0.00 0.7700 0.0004
DMA28C01A11DA16V10 3380A 0.976 MT-ND1 0.0003 R25Q 0.00 0.8800 MELAS 0.0004
DMA28G01A11DA16V10 7623T 0.967 MT-CO2 0.0000 T13I 0.00 0.7700 LHON
G4629401A11D180610 4222C 0.95 MT-ND1 0.0000 S306P 0.00 0.7800
G4629501A11D171910 6744A 0.792 MT-CO1 0.0000 G281S 0.00 0.7700
G4631501A11D171910 11711A 0.792 MT-ND4 0.0003 A318T 0.00 0.7800 0.0037
G4632001A11D171910 9384A 0.893 MT-CO3 0.0000 D60N 0.00 0.7800 0.0008
G4658801A11D177110 4004C 0.768 MT-ND1 0.0000 M233T 0.00 0.4800
Table 5  List of prioritized germline non-synonymous variants in COAD samples
Non-synonymous germline variants recognized on COAD-derived mtDNAs and prioritized according to the established criteria. Sample identi-
fier (individual ID), heteroplasmic fraction in blood and tumor tissues (HF blood/tumor), mtDNA locus (locus), site-specific nucleotide vari-
ability (Nt Var), amino acid change and variability (AA change and AA Var, respectively), Disease Score, somatic (+) or germline (−) nature 
(‘tumor-specific/germline’) of variants and frequencies in 1000 Genomes [as implemented in (Calabrese et al. 2014)] are associated with each 
variant allele. For full germline variants in COAD samples, see Supplementary Table 3—Germline
Individual ID Variant allele HF blood/tumor Locus Nt Var AA change AA Var Disease score 1000 genomes
G4629410A 9447C 1/1 MT-CO3 0.0000 Y81H 0.0155 0.7772 0.0012
AY619710A 9106G 1/0.88 MT-ATP6 0.0004 T194A 0.0009 0.6682
F4680710A 8861T 1/1 MT-ATP6 0.0017 T112 M 0.0276 0.5456
A6565710A 15434T 0.98/0.99 MT-CYB 0.0015 L230F 0.0016 0.7115 0.0008
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variants featured variability values lower than or equal to 
NVC, including 8 premature stop codons and 89 non-syn-
onymous variants. Seventy-one out of 89 (27 % of the total 
variants) showed a disease score higher than or equal to 
DST and low HF levels ranging between 0.006 and 0.156. 
Thus, the 71 blood-specific non-synonymous variants (bold 
type in Supplementary Table 3—BloodSpecific) were not 
prioritized as potentially pathogenic.
The lists of prioritized variants of COAD datasets 
obtained by removing the haplogroup-filtering step, did 
not differ from those obtained performing the whole multi-
step workflow, proving that there are not variants that may 
potentially affect function of gene/protein among the hap-
logroup-defining ones, underlying the good performance of 
our approach on cancer dataset.
Discussion
The assessment of the role of mitochondrial variants in the 
onset and/or progression of human diseases and cancer is 
a difficult task. It requires robust and statistically reliable 
methods to support clinicians in the functional investiga-
tion of variants potentially affecting protein function. The 
question of determining the potential pathogenicity of 
mtDNA variants is in fact a matter of debate among clini-
cians (McCormick et al. 2013). Because of the peculiarities 
of mitochondrial polyplasmic genetics, assignment of path-
ogenicity should take into account the degree of hetero-
plasmy, the haplogroup background, and even environmen-
tal factors (Wallace et al. 2003). Several methods have been 
recently published to meet these goals, such as mit-o-matic 
(Vellarikkal et al. 2015), MitImpact (Castellana et al. 2015) 
and MtSNPscore (Bhardwaj et al. 2009). Here, we contrib-
ute with a robust statistical approach based on the introduc-
tion of two thresholds, NVC and DST. NVC threshold is 
calculated from the updated site-specific nucleotide varia-
bility values in a large dataset of complete healthy genomes 
available in HmtDB database, whose sequence quality was 
supported by a correct haplogroup prediction (see “Materi-
als and methods”); DST is a statistically estimated robust 
threshold based on the pathogenicity predictions estimated 
by MutPred (Li et al. 2009), HumDiv- and HumVar-trained 
PolyPhen-2 models (Adzhubei et al. 2013), SNPs&GO, 
PhD-SNP (Capriotti et al. 2013), and PANTHER (Thomas 
and Kejariwal 2004), combined with the nucleotide vari-
ability distribution in the same HmtDB healthy dataset. To 
date, the information on biochemical and structural features 
of mitochondrial respiratory chain proteins are not so rich 
as for nuclear ones. Accordingly, all the in silico patho-
genicity predictions may not be reliable and hence they 
should be considered with caution, since the determinants 
of pathogenicity for an mtDNA variant are unclear. The 
integration of pathogenicity predictions with the functional 
assays is an essential and strongly recommended step to 
consolidate the validation for pathogenicity of an mtDNA 
variant. The prioritization workflow is fully implemented 
in MToolBox (Calabrese et al. 2014) thus contributing to 
highlight mitochondrial DNA variants as suitable candi-
dates for subsequent functional analyses in clinical stud-
ies—an issue which has often revealed to be problematic in 
analyses seeking correlations between mtDNA genotypes 
and disease phenotypes.
The in silico prioritization criteria here developed were 
established on the assumption that rare variants may more 
likely affect the gene/protein function than polymorphic 
variants (Bannwarth et al. 2013). In this context, we used 
the Macro Haplogroup Consensus Sequences to move the 
fixed evolutionary variants to the background and high-
light rare ones. These rare variants may be characterized by 
nucleotide variability values below the established cutoff, 
while their potential functional impact, particularly for non-
synonymous variants, may be assessed from the disease 
score definition. Variants mapping on the non protein-cod-
ing regions may be also prioritized by taking into account 
the filtering against the three references and the nucleotide 
variability cutoff (NVC) only. Pathogenicity data regarding 
tRNAs and rRNAs variants will be soon integrated in the 
proposed pipeline.
The application of the NVC and DST on the dataset of 
all possible non-synonymous variants (patho_table, https://
sourceforge.net/projects/mtoolbox/) suggested that the loci 
MT-ATP6, MT-ATP8 and MT-CYB harbor the variants fea-
turing the highest nucleotide variability values and number 
of sites. Accordingly, these genes seem to be the least con-
served regions of the human mtDNA and the most prone to 
harbor non-synonymous variants (Supplementary Fig. 4a), 
as previously reported in Mitomap. On the other hand, the 
distribution of disease scores related to all the potentially 
pathogenic variants occurring in the thirteen protein-coding 
regions did not show any gene-specific peculiarity (Supple-
mentary Fig. 4b).
We applied the prioritization workflow to LHON, COAD 
and ovarian cancer sample sets to validate the robustness of 
our approach.
The majority of the causative mutations expected (8 out 
of 11 LHON-causing mutations) on the LHON dataset was 
recognized as affecting function by the application of the 
whole stepwise prioritization workflow with the exception 
of the mutations m.3700G>A (MT-ND1), m.14502T>C 
(MT-ND6) and m.14484T>C (MT-ND6) (Supplementary 
Table 1). These mutations were kept out by the applica-
tion of chosen variability and/or disease score thresholds 
but were retained by the other filtering steps. Specifically, 
the mutation m.14484T>C was found in healthy individu-
als (0.11 % of total mtDNA genomes stored in HmtDB) 
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despite the high DS suggestive of its potential functional 
impact. Such mutation was formerly considered a non-
pathogenic variant, resulting in a conservative change 
into an amino acid with similar physiochemical proper-
ties (p.M64 V) (Mackey and Howell 1992) and found in 
population surveys without expressing any pathological 
phenotype (Achilli et al. 2012). However, it was previously 
assumed that it may exert a pathogenic potential if found 
in association with the haplogroups J and I (Achilli et al. 
2012). 12 % of LHON-derived sequences here analyzed 
harbored this mutation; among these, only two belong to 
haplogroup J1 whereas most of the genomes belong to 
the macro-haplogroup M (26 % of total). The mutation 
m.3700G>A, although absent from the healthy population 
and for this reason more likely to have a functional impact, 
was suggested to be benign by the disease score. It may be 
due to half of pathogenicity predictors used to calculate the 
disease score, suggesting this mutation as benign (Supple-
mentary Table 1—AllVariants sheet). This points out that 
pathogenicity predictions should always be treated with 
caution and that functional validation of variants is of par-
amount importance to clarify their role in contributing to 
phenotype, especially in the context of specific haplogroups 
and upon taking into account that penetrance is a cogent 
clinical issue particularly in canonical mitochondriopa-
thies such as LHON. The mutation m.14502T>C, excluded 
since predicted as benign and found in the healthy popula-
tion, is reported in the literature in sporadic LHON cases 
and/or in combination with other primary LHON muta-
tions (Zhao et al. 2009; Zhang et al. 2010). In addition, 
our study suggested a pool of new variants not previously 
associated with LHON warranting further investigation 
with the aim to recognize novel causative mutations which 
could be added in the list of “top 14” LHON-specific muta-
tions (Brandon et al. 2005). Finally, two additional variants 
were prioritized removing the haplogroup-filtering step. 
This result does not imply that our prioritization process 
may give false negatives because the output of the pipeline 
reports the entire list of variants with the prioritized ones 
at the top. The user is free to filter the variants according 
to his preferred criteria. The system simply suggests and 
reports the thresholds that may facilitate the selection of 
functional important variants.
With respect to cancer, it needs to be underlined that our 
workflow may provide an additional advantage, namely the 
efficient selection of potentially affecting function vari-
ants that are candidates for being somatic that only trans-
formed cells may withstand, in the context of a deregulated 
cell metabolism. For too long, associations between cancer 
types and mtDNA variants have been reported without veri-
fying whether they were somatic or germline, in which lat-
ter case they may be speculated to be predisposing to trans-
formation. Even further, many polymorphisms have been 
classified in the past years as cancer-associated mtDNA 
mutations (Máximo and Sobrinho-Simões 2000; Setiawan 
et al. 2008), a risky statement likely driven by the lack of 
well-curated databases and of a commonly agreed protocol 
to define such associations. The high frequency of mtDNA 
variants that is often detected in cancer samples may also 
be a great obstacle to select few candidates to bring for-
ward to functional studies, with the aim to assess in which 
way they may impact metabolism. This is a key step that 
this workflow intends to simplify, as we have shown in both 
COAD and ovarian cancer sample sets by verifying the 
somatic nature of prioritized variants. However, we have 
here shown that our criteria are not too stringent, as they 
allow inclusion of a few variants that were not found to be 
somatic. Although this finding may somewhat decrease the 
performing index of our workflow in highlighting specifi-
cally cancer-associated mutation, it may on the other hand 
permit to select variants that may still affect the gene/pro-
tein function, even though not associated to the patient’s 
disease.
In this paper, we successfully demonstrate that the pri-
oritization of human mtDNA variants based on the work-
flow here proposed is able to recognize potential affect-
ing function variants. Compared to the existing pipelines, 
capable of annotating mitochondrial variations from next-
generation datasets exclusively (mit-o-matic, Vellarikkal 
et al. 2015), or extract information from lists of variants 
or FASTA sequences exclusively (MtSNPscore, Bhardwaj 
et al. 2009), our prioritization workflow, currently being 
implemented in MToolBox, appears to be more flexible 
allowing a functional annotation of variants on large data-
sets from both next-generation (in BAM, SAM, FASTQ 
format) and Sanger sequencing (in FASTA format) data.
Finally, the recent publication of MitImpact (Castellana 
et al. 2015) reports a database of the entire dataset of non-
synonymous human mtDNA variants annotated with nucle-
otide variability available through the HmtDB resource and 
pathogenicity scores estimated by applying the same pre-
dictors implemented in MToolBox, with three additional 
ones. The estimation of the level of concordance among 
predictions is provided through two alternative “uniformity 
scores”, similar to our percentage of concordance, previ-
ously implemented in MToolBox and now replaced by the 
disease scores here reported. The different type of inputs 
required by mit-o-matic, MitImpact and MtSNPscore did 
not allow to report here the results of a quantitative com-
parison with MToolBox. Those results may be roughly 
comparable according to predicted pathogenicity of the 
considered variants.
In conclusion, our prioritization workflow based on (1) 
the use of MHCSs together with RSRS and rCRS, to fil-
ter out variants fixed during evolution; (2) the availability 
of the NV scores obtained through the HmtDB annotated 
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genomes and (3) the implementation of the NVC and DST, 
reducing the large amount of variants from both NGS and 
conventional Sanger technologies, offers one of the most 
complete tools to guide clinicians in selecting the non-
synonymous mtDNA variants with a potential functional 
impact. However, functional assays are strongly required to 
confirm the pathogenicity of all mtDNA variants prioritized 
by this workflow, as well as by any automated method, 
with the aim to establish their exact role and involvement in 
disease phenotypes.
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